GlaxoSmithKline announced that Tanzeum (albiglutide) subcutaneous injection is now available.
Results announced from nine new Phase 3 ODYSSEY trials of alirocumab (Sanofi and Regeneron) in patients with hypercholesterolemia.
Regeneron announced that the FDA has approved Eylea (aflibercept) injection for the treatment of diabetic macular edema (DME).
Hospira announced a voluntary recall of one lot of Lidocaine HCl Injection, 2% due to a report of discolored solution with visible particles.
New research has identified over two dozen genetic risk factors involved in Parkinsonism, including six that were previously unknown.